IMPACT OF THE COVID-19 PANDEMIC ON CERVICAL CANCER SCREENING IN SAOPAULO STATE, BRAZIL
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
MARTINS, Toni Ricardo
WITKIN, Steven S.
MENDES-CORREA, Maria Cassia
GODOY, Amanda Scancella de
CURY, Lise
BALANCIN, Marcelo Luiz
AB'SABER, Alexandre Muxfeldt
PERES, Stela Verzinhasse
MESSIAS, Sandra
MENDONZA, Tania Regina Tozetto
Citação
ACTA CYTOLOGICA, v.67, n.4, p.388-394, 2023
Resumo
INTRODUCTION: The early identification of precursor lesions followed by appropriate treatment prevents development of cervical cancer and its consequences OBJECTIVE: The present study evaluated the influence of the Covid-19 pandemic on cervical cancer screening by comparing the quantity of tests to detect cervical cellular changes performed in Sao Paulo state in 2019, prior to the detection of SARS-CoV-2 in Brazil, to the first (2020) and second (2021) years following its appearance. MATERIALS AND METHODS: Data from Fundacao Oncocentro de Sao Paulo (FOSP), the agency that analyses approximately 220,000 Pap tests annually, was reviewed. RESULTS: A median of 1835 Papanicolaou (Pap) tests were performed in 55 municipalities in 2019. This was reduced to 815 tests in 2020, a 56% decrease (p = 0.0026). In 2021, the median number was 1745, a 53% increase over 2020 levels (p = 0.0233). The 26 municipalities with >1000 tests in 2020 had a median reduction from 4433 in 2019 to 2580 in 2020 (p = 0. 0046). The 29 municipalities with <1000 tests had a median reduction from 951 in 2019 to 554 in 2020 (p < 0.0001). There was a 44% reduction in the number of follow-up cytological evaluations from 2019 to 2020, followed by a 30% increase the following year. However, the percentage of women with a normal finding or with any abnormality remained unchanged. The findings from a histological evaluation of women in Sao Paulo city indicated that the percent of cases positive for CIN-1 (p<0.0410) and CIN-3 (p<0.0012) increased in 2020 and 2021 as compared to 2019 levels. CONCLUSION: A reduction in testing for cervical cancer in the first year of the Covid-19 pandemic, accompanied by an elevated incidence of precancerous lesions in each of the first two years following its initiation, may portend a subsequent increased occurrence of cervical cancer in Brazil.
Palavras-chave
Referências
- Ajenifuja KO, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00325-4
- Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945
- [Anonymous], 2021, NOT PAND DERR QUAS 3
- [Anonymous], DIAGNOSTICO CANC TRA
- [Anonymous], 2020, REV BRAS CANCEROL
- [Anonymous], COVID 19 DATA REPOSI
- [Anonymous], 2020, PAIN COV IMP COVID T
- Bakouny Z, 2021, JAMA ONCOL, V7, P458, DOI 10.1001/jamaoncol.2020.7600
- Equipe Oncoguia, 2020, PAND RED EX DIAGN CA
- Fundacao Oncocentro de Sao Paulo, DIR ADJ LAB
- Ginsburg O, 2021, NAT CANCER, V2, P133, DOI 10.1038/s43018-021-00178-9
- Grupo Tecnico de Avaliacao e Informacoes de Saude (Gais), 2021, RES SES PERF PROF DA, P103
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2019, COORD PREV VIG EST 2
- Mayo MacKenzie, 2021, Mayo Clin Proc Innov Qual Outcomes, V5, P1109, DOI 10.1016/j.mayocpiqo.2021.10.003
- Ribeiro A, 2021, CANCER PREV RES, V14, P919, DOI 10.1158/1940-6207.CAPR-21-0110
- Simms KT, 2019, LANCET ONCOL, V20, P394, DOI 10.1016/S1470-2045(18)30836-2
- Villain P, 2021, INT J CANCER, V149, P97, DOI 10.1002/ijc.33500
- World Health Organization (WHO), CERV CANC
- Zhou Peng, 2020, Nature, V588, pE6, DOI 10.1038/s41586-020-2951-z